Figure 4.
Distribution of the Proportional Reporting Ratio (P.R.R.) of different risks vs. the IC50 values of the drugs against the different recombinant KATP channel subunit combination expressed in cell lines. P.R.R. values lower than 1 indicate low risk; values higher than 1 indicate higher risk. Zoledronic acid shows a high risk for all A.D.R. apart from hypoglycaemia and rhabdomyolysis, and the highest potency against the vascular KIR6.1-SUR2B channels vs. other drugs. The sulfonylureas and glinides show a higher risk for hypoglycemia and muscular weakness, and nateglinide shows additional risks for cardiac A.D.R. and rhabdomyolysis. The sulfonylureas and glinides show the highest potency against the pancreatic KIR6.2-SUR1 channels vs. zoledronic acid except for nateglinide, which is the less potent drug within the glinides and sulfonylureas.